This research aimed to create a prostate specific antigen (PSA) and alpha 1-antichymotrypsin (ACT) complex (PSA-ACT) for use as a calibrator in immunoassays for detecting prostate cancer. The researchers mixed and incubated PSA with ACT to form a complex, then purified the complex using gel filtration and ion-exchange chromatography. Analysis with SDS-PAGE and chromatography confirmed formation of the PSA-ACT complex. While purity was low, the synthesized PSA-ACT was comparable to commercially available standards. The purified complex could potentially be used as a calibrator to improve prostate cancer detection and monitoring.
1) The document discusses several studies presented as posters at the 27th Annual EAU Congress in Paris that evaluate the prostate health index (phi) test in detecting prostate cancer.
2) One study found phi and its derivatives %p2PSA and p2PSA were more accurate than PSA and %fPSA in predicting prostate cancer in men undergoing repeat biopsy. Using specific cut-off levels avoided many biopsies while missing few aggressive cancers.
3) Another study estimated that using phi in addition to PSA screening could reduce unnecessary biopsies by 29% while maintaining cancer detection rates, improving cost-effectiveness.
The 4Kscore® blood test for risk of aggressive prostate cancerOPKO Labs
The 4Kscore blood test uses PSA, free PSA, intact PSA and hK2 levels, along with other factors, to predict an individual's risk of having aggressive prostate cancer. It was developed over 10 years working with over 22,000 men. A US study of over 1,000 men validated that the 4Kscore accurately identified those with aggressive prostate cancer detected on biopsy. The test has greater accuracy than PSA alone and can help guide decisions on whether a biopsy is needed. Its risk assessment is included in NCCN guidelines for early prostate cancer detection.
A series of Be Clear on Cancer awareness events were held prior to the campaign launch in Autumn 2013. These slides are from the London event on 10 September 2012
The events included:
An update on the 'Blood in Pee' campaign Oct-Nov 2013
Sharing experiences from BCOC pilots
A review of the impact of the BCOC campaigns
Latest plans for BCOC February 20145 campaigns
An opportunity for delegates to feedback on experience of campaigns and make suggestions for improvement
Events were aimed at SCNs - Programme leads, Clinicians, Public Health, National NAEDI Partners - DH, Public Health England, NHS England and Charities
June is cancer awareness month at Staff Management | SMX. To promote cancer awareness across our company, the Diversity Program Inclusion Council created this presentation to share statistics, cancer facts and testimonials from two Staff Management | SMX cancer survivors.
Early Detection of Breast Cancer: Awareness and Practice of Self Breast Exami...iosrjce
IOSR Journal of Dental and Medical Sciences is one of the speciality Journal in Dental Science and Medical Science published by International Organization of Scientific Research (IOSR). The Journal publishes papers of the highest scientific merit and widest possible scope work in all areas related to medical and dental science. The Journal welcome review articles, leading medical and clinical research articles, technical notes, case reports and others.
Prostate cancer detection, UroLifts, HaematuriaMarc Laniado
This document discusses innovations in prostate disease management, including focal therapy options for prostate cancer and the UroLift procedure for treating benign prostatic hyperplasia (BPH). It summarizes guidelines for investigating hematuria and evaluating prostate cancer risk. It also compares treatment options for localized prostate cancer and BPH, noting UroLift offers symptom relief while preserving sexual function unlike other BPH treatments. Clinical data shows UroLift improves urinary symptoms and quality of life compared to TURP, with faster recovery and no effect on ejaculation.
This research aimed to create a prostate specific antigen (PSA) and alpha 1-antichymotrypsin (ACT) complex (PSA-ACT) for use as a calibrator in immunoassays for detecting prostate cancer. The researchers mixed and incubated PSA with ACT to form a complex, then purified the complex using gel filtration and ion-exchange chromatography. Analysis with SDS-PAGE and chromatography confirmed formation of the PSA-ACT complex. While purity was low, the synthesized PSA-ACT was comparable to commercially available standards. The purified complex could potentially be used as a calibrator to improve prostate cancer detection and monitoring.
1) The document discusses several studies presented as posters at the 27th Annual EAU Congress in Paris that evaluate the prostate health index (phi) test in detecting prostate cancer.
2) One study found phi and its derivatives %p2PSA and p2PSA were more accurate than PSA and %fPSA in predicting prostate cancer in men undergoing repeat biopsy. Using specific cut-off levels avoided many biopsies while missing few aggressive cancers.
3) Another study estimated that using phi in addition to PSA screening could reduce unnecessary biopsies by 29% while maintaining cancer detection rates, improving cost-effectiveness.
The 4Kscore® blood test for risk of aggressive prostate cancerOPKO Labs
The 4Kscore blood test uses PSA, free PSA, intact PSA and hK2 levels, along with other factors, to predict an individual's risk of having aggressive prostate cancer. It was developed over 10 years working with over 22,000 men. A US study of over 1,000 men validated that the 4Kscore accurately identified those with aggressive prostate cancer detected on biopsy. The test has greater accuracy than PSA alone and can help guide decisions on whether a biopsy is needed. Its risk assessment is included in NCCN guidelines for early prostate cancer detection.
A series of Be Clear on Cancer awareness events were held prior to the campaign launch in Autumn 2013. These slides are from the London event on 10 September 2012
The events included:
An update on the 'Blood in Pee' campaign Oct-Nov 2013
Sharing experiences from BCOC pilots
A review of the impact of the BCOC campaigns
Latest plans for BCOC February 20145 campaigns
An opportunity for delegates to feedback on experience of campaigns and make suggestions for improvement
Events were aimed at SCNs - Programme leads, Clinicians, Public Health, National NAEDI Partners - DH, Public Health England, NHS England and Charities
June is cancer awareness month at Staff Management | SMX. To promote cancer awareness across our company, the Diversity Program Inclusion Council created this presentation to share statistics, cancer facts and testimonials from two Staff Management | SMX cancer survivors.
Early Detection of Breast Cancer: Awareness and Practice of Self Breast Exami...iosrjce
IOSR Journal of Dental and Medical Sciences is one of the speciality Journal in Dental Science and Medical Science published by International Organization of Scientific Research (IOSR). The Journal publishes papers of the highest scientific merit and widest possible scope work in all areas related to medical and dental science. The Journal welcome review articles, leading medical and clinical research articles, technical notes, case reports and others.
Prostate cancer detection, UroLifts, HaematuriaMarc Laniado
This document discusses innovations in prostate disease management, including focal therapy options for prostate cancer and the UroLift procedure for treating benign prostatic hyperplasia (BPH). It summarizes guidelines for investigating hematuria and evaluating prostate cancer risk. It also compares treatment options for localized prostate cancer and BPH, noting UroLift offers symptom relief while preserving sexual function unlike other BPH treatments. Clinical data shows UroLift improves urinary symptoms and quality of life compared to TURP, with faster recovery and no effect on ejaculation.
The reasons for late diagnosis of nephrotuberculosisМаксим Зеленский
The document discusses reasons for late diagnosis of nephrotuberculosis. It found that the majority (93.4%) of patients had a chronic disease with symptoms for an average of 27.3 months before diagnosis. Most patients (62.2%) had cavernas visible on x-ray rather than papillitis (37.8%). The treatment outcomes were optimal in only around half of patients (49.7% and 24.7% respectively), with the majority having nonoptimal outcomes (75.3% and 20.3%).
The document provides an agenda for press events at the AUA PRESS PROGRAM occurring from May 14-17, 2011. It lists the date, time, title, abstract numbers, and moderator for various panel discussions and presentations covering topics in urology including public health issues, erectile dysfunction, prostate cancer, kidney cancer, prostate-specific antigen testing, pediatric urology, smoking outcomes, and lifestyle impacts on stone disease. Conference call information is provided to access audio of the press events.
«Персонифицированный подход к лечению пациентов с ДГПЖ»
1. Уважаемый доктор!
Приглашаем Вас принять участие
в научном симпозиуме
«Персонифицированный подход к лечению
пациентов с ДГПЖ»,
который состоится в рамках
XIII конгресса Российского общества урологов
7 ноября 2013г
выставочный центр «Крокус Экспо»
павильон N3, 4 этаж
выставочный зал №20
малый зал №2
Время проведения симпозиума 17.00–18.30
ВСЕ УЧАСТНИКИ СИМПОЗИУМА
БУДУТ ИМЕТЬ ВОЗМОЖНОСТЬ ПОЛУЧИТЬ КНИГУ
ХАММ Б., АСБАХ П., БЕЙЕРСДОРФ Д.,
ХАЙН П., ЛЕМКЕ У.
«ЛУЧЕВАЯ ДИАГНОСТИКА.
БОЛЕЗНИ МОЧЕПОЛОВОЙ СИСТЕМЫ»
Сопредседатели:
профессор Пушкарь Д.Ю.
(Главный уролог Минздрава РФ, заведующий
кафедрой урологии МГМСУ)
ЕК
ЕЛ
С
РО
У
Ь
СТ
НО
В
ТИ
профессор Сивков А.В.
(Первый заместитель директора ФГБУ «НИИ
Урологии» Минздрава РФ)
профессор Мартов А.Г.
(Заведующий кафедрой урологии ИПК ФМБА)
Программа симпозиума
К
ФЕ
ЭФ
Ь
СТ
НО
В
ТИ
Пушкарь Д.Ю.
«Качество жизни пациента с ДГПЖ»
Сивков А.В.
«Критерии эффективности силодозина
при лечении ДГПЖ»
Мартов А.Г.
«Альфа-адреноблокаторы в лечении нарушений
мочеиспускания после трансуретральной
резекции предстательной железы»
ТЬ
ОС
БЕ
ЗО
СН
ПА
2. XIII Конгресс
Российского общества урологов
Научный симпозиум
компании Рекордати
«Персонифицированный
подход к лечению пациентов
с ДГПЖ»
27 ноября 2013г.,
Москва, м. Мякинино, 65-66 км МКАД
Выставочный центр «Крокус Экспо»
Павильон N3, 4 этаж, выставочный зал №20
Малый зал №2
UROREC.xx/xx/xx
Начало в 17.00
ООО «Русфик», 123610, Москва,
Краснопресненская набережная д.12, ЦМТ, подъезд 7, этаж 6, офис 605-608
Тел. (495) 258-20-06; e-mail: info@rusfic.com; www.rusfic.ru